BBIO — BridgeBio Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1743881 ·
Last close
$65.57
Market Cap
$12.82B
52W High
$93.42
52W Low
$48.88
ADV30
2,466,013
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 243,676,000 | 228,630,000 | -107,079,000 | -152,216,000 | 1,217,299,000 | 677,911,000 | 3,723,192,000 |
| Mar 2026 | 194,515,000 | 184,576,000 | -105,956,000 | -164,043,000 | 1,370,981,000 | 879,891,000 | 3,639,856,000 |
| Dec 2025 | 154,178,000 | 146,071,000 | -128,431,000 | -192,863,000 | 936,025,000 | 570,119,000 | 3,012,606,000 |
| Sep 2025 | 120,700,000 | 114,137,000 | -136,358,000 | -182,743,000 | 998,250,000 | 642,951,000 | 2,920,979,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-443,954,000
Investing CF
$-65,627,000
Financing CF
$848,857,000
CapEx
$-8,066,000
Dividends Paid
—
Buybacks
$-99,024,000
EPS Diluted TTM
$-3.74
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,985,237,000
Inventory
$32,980,000
Receivables
$205,226,000
ST Investments
$60,295,000
EBIT TTM
$-540,535,000
Pretax Income TTM
$-729,450,000
Interest Exp TTM
$188,915,000
Analysts
21
Yahoo Snapshot (yfinance, live)
Total Revenue
$713,068,992
EBITDA
$-472,752,000
Free Cash Flow
$-320,264,128
Enterprise Value
$16,823,425,024
Total Cash
$720,160,000
Total Debt
$3,373,149,952
Shares Out
195,492,997
Trailing EPS
$-3.56
Book Value
$-12.88
ROE
—
ROA
-26.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 502,076,000 | -502,064,000 | -724,931,000 | 936,025,000 | 3,012,606,000 | -2,086,610,000 | -445,910,000 |
| Dec 2024 | 221,902,000 | -577,368,000 | -535,762,000 | 919,338,000 | 2,376,950,000 | -1,467,904,000 | -520,726,000 |
| Dec 2023 | 9,303,000 | -599,444,000 | -643,202,000 | 546,380,000 | 1,888,915,000 | -1,354,257,000 | -527,720,000 |
| Dec 2022 | 77,648,000 | -468,437,000 | -481,183,000 | 623,036,000 | 1,867,960,000 | -1,254,617,000 | -419,494,000 |
TTM Snapshot
Revenues TTM
$119,365,000
NetIncome TTM
$-329,462,000
OpCashFlow TTM
$0
Assets (Latest)
$936,025,000
Forward EPS
$0.03
Max Pain — expiry 2026-10-16
max pain strike: $70.00 · spot: $64.81 · call oi: 2,919 · put oi: 10,197
Expected Move to 2026-10-16:
±$6.22
(9.60%) —
implied range
$58.59 –
$71.03
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.55B | $116.10 | — |
| SMMT | Summit Therapeutics Inc. | $12.45B | $15.61 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.93B | $516.56 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.66B | $60.26 | — |
| ELAN | Elanco Animal Health Inc | $11.14B | $22.31 | — |
News headlines (Yahoo Finance, 1h cache)
The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis
2026-09-27 23:10 · Yahoo
BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data Lands
2026-09-27 14:07 · Yahoo
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
2026-09-26 08:02 · Yahoo
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 20:01 · Yahoo
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
2026-09-09 15:30 · Yahoo
BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis?
2026-09-04 16:18 · Yahoo
BridgeBio to Participate in September Investor Conferences
2026-09-01 11:30 · Yahoo
BridgeBio (BBIO) Stock Looks Fully Priced Despite Fresh Acoramidis Data
2026-09-01 03:08 · Yahoo
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
2026-09-02 22:00 · Yahoo
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
2026-09-01 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.